NFKB1 and glioblastoma: While genetic or pharmacological targeting of IL-1β successfully reduced monocyte recruitment and improved survival in proneural GBM models, this approach was ineffective in mesenchymal subtypes due to the presence of constitutively active NF-κB signaling, underscoring the need for subtype-specific therapeutic strategies [17].